EDX Medical Group PLC is a UK-based enterprise that focuses on developing and providing innovative medical diagnostic tests to enhance the early detection and characterization of major diseases, including cancer and infectious diseases. The company operates a molecular biology and diagnostics laboratory in Cambridge, UK, which is accredited to ISO 15189 (2022) by the United Kingdom Accreditation Service (UKAS). The company's product portfolio features proprietary tests and laboratory services, including advanced bowel and testicular cancer testing, a pneumonia test for intensive care units, and a test for assessing chemotherapy treatment toxicity. These products are marketed to various clients, including patients, general practitioners, healthcare providers, private hospitals, insurers, and the National Health Service (NHS). EDX Medical Group PLC was incorporated on March 19, 2021, and has a current market capitalization of approximately £40.1 million. Formerly known as TECC Capital PLC, the company changed its name to EDX Medical Group PLC in November 2022. EDX was admitted to the London Stock Exchange AIM on May 13, 2026. The company's registered office is situated at 210-211 Science Park, Milton Road, Cambridge, CB4 0WA, United Kingdom. The CEO of EDX Medical Group PLC is Michael Hudson. Additionally, the company has completed two acquisitions: Hutano Diagnostics and Torax Biosciences. EDX Medical Group operates in a competitive market, with competitors including EKF, LumiraDx, and others.
AI-researched from public web sources — may contain errors or omissions and is not a substitute for verifying independently.
EDX Medical Group PLC's offering is currently announced on AIM. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with EDX Medical Group PLC.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/edx-medical-group" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="EDX Medical Group PLC — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/edx-medical-group?theme=light as the src instead.
https://www.discoveripo.com/ipo/edx-medical-group/opengraph-image
EDX Medical Group PLC IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/edx-medical-group?utm_source=embed&utm_medium=text&utm_campaign=edx-medical-group
Get emailed when EDX Medical Group PLC's terms, price, or expected date change — no weekly noise, just this company.
EDX Medical Group PLC is listing on AIM.
EDX Medical Group PLC is a UK-based enterprise that focuses on developing and providing innovative medical diagnostic tests to enhance the early detection and characterization of major diseases, including cancer and infectious diseases. The company operates a molecular biology and diagnostics laboratory in Cambridge, UK, which is accredited to ISO 15189 (2022) by the United Kingdom Accreditation Service (UKAS). The company's product portfolio features proprietary tests and laboratory services, including advanced bowel and testicular cancer testing, a pneumonia test for intensive care units, and a test for assessing chemotherapy treatment toxicity. These products are marketed to various clients, including patients, general practitioners, healthcare providers, private hospitals, insurers, and the National Health Service (NHS). EDX Medical Group PLC was incorporated on March 19, 2021, and has a current market capitalization of approximately £40.1 million. Formerly known as TECC Capital PLC, the company changed its name to EDX Medical Group PLC in November 2022. EDX was admitted to the London Stock Exchange AIM on May 13, 2026. The company's registered office is situated at 210-211 Science Park, Milton Road, Cambridge, CB4 0WA, United Kingdom. The CEO of EDX Medical Group PLC is Michael Hudson. Additionally, the company has completed two acquisitions: Hutano Diagnostics and Torax Biosciences. EDX Medical Group operates in a competitive market, with competitors including EKF, LumiraDx, and others.
The UK Financial Conduct Authority's National Storage Mechanism — an intention-to-float or AIM pre-admission announcement date, not a confirmed first-dealings date. Retrieved Sep 17, 2026.
View the original filing on FCA NSM →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy